About Ubiquitin-like-conjugating enzyme ATG3
Ubiquitin-like-conjugating enzyme ATG3 (ATG3) is a protein
from Homo sapiens identified by UniProt accession
Q9NT62, 314 residues long.
MolForge cross-references it against 0 known binders and
125 disease associations.
Target properties
| Protein name | Ubiquitin-like-conjugating enzyme ATG3 |
|---|
| UniProt accession | Q9NT62 |
|---|
| Gene | ATG3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 314 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (125)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.56
- lysosomal storage disease · score 0.29
- breast adenocarcinoma · score 0.18
- eosinophil count · score 0.17
- acute myeloid leukemia · score 0.08
- non-small cell lung carcinoma · score 0.07
- hepatocellular carcinoma · score 0.04
- viral disease · score 0.03
- eosinophil percentage of leukocytes · score 0.03
- neoplasm · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NT62-F1 | alphafold | PREDICTED | 73.41 | — |
Amino-acid sequence (314 residues)
MQNVINTVKG KALEVAEYLT PVLKESKFKE TGVITPEEFV AAGDHLVHHC PTWQWATGEE LKVKAYLPTG KQFLVTKNVP CYKRCKQMEY SDELEAIIEE DDGDGGWVDT YHNTGITGIT EAVKEITLEN KDNIRLQDCS ALCEEEEDED EGEAADMEEY EESGLLETDE ATLDTRKIVE ACKAKTDAGG EDAILQTRTY DLYITYDKYY QTPRLWLFGY DEQRQPLTVE HMYEDISQDH VKKTVTIENH PHLPPPPMCS VHPCRHAEVM KKIIETVAEG GGELGVHMYL LIFLKFVQAV IPTIEYDYTR HFTM
Explore Ubiquitin-like-conjugating enzyme ATG3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets